Pancreatic Cancer Research

ResearcherCedars-Sinai Medical CenterNo recent work listed

Harold Phillip Koeffler

Matched on ORCID iD 0000-0001-5839-9913; OpenAlex author ID A5082903377. Sources: OpenAlex.

Their work

Papers
6 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper

Papers 6

  1. Overexpression of laminin-5 gamma-2 promotes tumorigenesis of pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/mTOR cascade. Co-author DOI 10.1007/s00018-022-04392-1↗
  2. Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib. Last author DOI 10.7150/jca.25138↗
  3. Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Last author DOI 10.1016/j.molonc.2015.01.002↗
  4. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR… Last author DOI 10.1002/mc.22024↗
  5. Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells. Last author DOI 10.18632/oncotarget.2051↗
  6. PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells. Last author DOI 10.1038/bjc.2013.531↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Manoj Garg · 3 shared papers, 2014–2022 · strength 0.26
  2. Wenwen Chien · 5 shared papers, 2013–2018 · strength 0.22
  3. Anuradha Kirtonia · 1 shared paper, 2022 · strength 0.16
  4. David W. Dawson · 1 shared paper, 2022 · strength 0.16
  5. Yun Zheng · 2 shared papers, 2014–2018 · strength 0.10
  6. Hiroyuki Kato · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.